###### Strengths and limitations of this study

-   It is possible that the sample size was too small to show the impact of HIV-specific characteristics on mortality.

-   The age-matched controls were only able to be matched within a decade due to the relatively young age of patients infected with HIV at *Staphylococcus aureus* bacteraemia diagnosis. For this reason, we adjusted for age in all analyses.

-   Strengths of this study are the long study period as well as the long follow-up time.

Introduction {#s1}
============

*Staphylococcus aureus* is a frequent cause of bacteraemia, and the risk of *S aureus* bacteraemia (SAB) increases with HIV infection.[@R1]^--^[@R5] Although the use of antiretroviral therapy (ART) has decreased this risk considerably, it remains 15-fold higher than in the general population and varies widely among HIV risk groups.[@R6] Injection drug users (IDU) have rates of infection that are 100-fold higher than the general population, while men who have sex with men and heterosexuals have rates that are 5--10-fold higher.[@R6] Additionally, individuals with HIV infection have a sixfold higher rate of reinfection than individuals without HIV infection.[@R7] While mortality associated with SAB has decreased over the past decades, this has not been studied specifically for HIV infection.[@R8] ^--^[@R11]

We performed a case--control study to better understand the differences in short-term outcome as well as the rate and risk of reinfection after SAB in HIV-1-infected individuals compared to individuals without HIV-1 infection.

Materials and methods {#s2}
=====================

The study was carried out at Hvidovre Hospital, University of Copenhagen, Denmark. We retrospectively reviewed medical records from HIV-1-infected individuals with SAB and age-matched (within a decade) and sex-matched individuals without HIV infection with SAB. The study was conducted between 1 January 1995 and 31 December 2010. Our clinic follows a third of the estimated 5000 individuals with HIV infection in Denmark.

Individuals with SAB were identified by merging the Danish Staphylococcal Database,[@R8] [@R12] the Danish HIV Cohort[@R13] and the database at the Department of Clinical Microbiology at Hvidovre Hospital*.*

The date of death or loss to follow-up among cases and controls was collected from the Danish Civil Registration System that tracks daily changes in vital status, including date of emigration and date of death, for the entire Danish population.[@R14]

Hospital-acquired SAB was defined as a positive blood culture taken \>48 h after admission. Healthcare-associated SAB included individuals in regular haemodialysis or regular intravenous infusions of chemotherapy or antivirals. Community-acquired SAB included a positive blood culture taken \<48 h after admission and no presence of healthcare-associated SAB. We defined a case of reinfection as an individual with \>1 episode of SAB at least 90 days apart.

The medical records were examined in detail to gather clinical, microbiological, vital and laboratory data at the time of blood culture. The most recent CD4 T-lymphocyte count and plasma HIV RNA level within 3 months of blood culture was used. The nadir CD4 T-lymphocyte count was the lowest count detected at any time prior to SAB. Severity of acute illness was assessed using the Pitt bacteraemia score within 48 h before or on the day of first positive blood culture.[@R15] [@R16] The highest point score on the basis of fever, hypotension, mechanical ventilation, cardiac arrest and mental status within that time was recorded.

For each patient, any comorbidity (ischaemic heart disease, chronic heart failure, chronic arterial hypertension, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, diabetes, cancer and autoimmune disease) or AIDS defining disease at the time of blood culture was registered.

Antibiotic therapy was registered as relevant when given within 48 h from collection of positive blood culture with a relevant β-lactam (dicloxacillin, cefuroxime, piperacillin/tazobactam), carbapenem or vancomycin at sufficient dosage. The effectiveness of the given antibiotic was crosschecked with antibiotic susceptibility testing for each patient. No antibiotic therapy or monotherapy with an aminoglycoside or rifampicin was deemed inadequate.

Typing of isolates {#s2a}
------------------

Clonal complexes (CC) were identified based on spa gene (encoding *S aureus* protein A) typing as previously described.[@R17] [@R18]

Statistics {#s2b}
----------

All values are expressed as median and range unless otherwise stated. Differences in continuous values were tested with the Mann-Whitney U test.

OR with 95% CIs were computed using logistic regression. Only variables that were \>90% complete were evaluated. Variables with more than 10% missing were excluded from analysis. Variables that were associated with mortality in univariate analysis at a significance level of p\<0.1 were included in multivariate analysis. The goodness of fit of the model was tested with the Hosmer-Lemeshow test,[@R19] which revealed adequate model fit (p=0.74). Incidence rates were calculated with 95% CI. Time to reinfection curves were constructed by the method of Kaplan-Meier. Analyses were performed using SPSS V.20.0 (SPSS Inc, Chicago, Illinois, USA).

Results {#s3}
=======

A total of 245 individuals were included in the study; 82 HIV-1-infected individuals and 163 individuals without HIV infection.

Demographic characteristics at baseline are shown in [table 1](#BMJOPEN2013004075TB1){ref-type="table"}. The majority of individuals were male (59.2%). The median age of the individuals was 40 years (range 18--86), but individuals with HIV infection were slightly younger than the HIV uninfected. All individuals were followed for a total of 8.4 (2.6--13.0) years; individuals with HIV infection for 9.2 (1.0--12.9) years and individuals uninfected with HIV for 8.2 (3.5--13.1) years (p=0.65). One-hundred and ninety (79.6%) individuals received relevant antibiotic therapy within 48 h of blood culture. Of the 50 inadequately treated, 21 were HIV infected. By 72 h, 217 (88.6%) received relevant antibiotic therapy. A total of 13 patients were not treated with antibiotics.

###### 

Characteristics of individuals with *Staphylococcus aureus* bacteraemia with and without HIV-1 infection

                                All n=245     HIV-1 infected n=82   HIV-1 uninfected n=163   p Value
  ----------------------------- ------------- --------------------- ------------------------ ---------
  Age, years (range)            40 (18--86)   37 (18--79)           41 (19--86)              0.03
  Male (%)                      145 (59.2)    49 (59.8)             96 (58.9)                --
  Nationality (%)                                                                            
   Danish/European              222 (90.6)    73 (89)               149 (91.4)               
   Non-European                 23 (9.4)      9 (11)                14 (8.6)                 0.64
  MRSA (%)                      5 (2.0)       3 (3.7)               2 (1.2)                  0.33
  Origin (%)                                                                                 
   Community                    156 (63.7)    62 (75.6)             94 (57.7)                
   Hospital                     69 (28.2)     15 (19.5)             53 (32.5)                
   Healthcare associated        20 (8.1)      4 (4.9)               16 (9.8)                 0.02
  IDU (%)                                                                                    
   No                           139 (56.7)    39 (47.6)             100 (61.3)               
   Current                      99 (40.4)     42 (51.2)             57 (35.0)                
   Former                       7 (2.9)       1 (1.2)               6 (3.7)                  0.04
  Entry (%)                                                                                  
   Surgical                     9 (3.7)       2 (2.4)               7 (4.3)                  
   Skin infection               60 (24.5)     17 (20.7)             43 (26.4)                
   Intravenous line             29 (11.8)     10 (12.2)             19 (11.7)                
   Active IDU                   77 (31.4)     36 (43.9)             41 (25.2)                
   Other                        17 (6.9)      2 (2.4)               15 (9.2)                 
   Unknown                      53 (21.6)     15 (18.3)             38 (23.2)                0.04
  Secondary manifestation (%)                                                                
   None                         163 (66.8)    54 (66.7)             109 (66.9)               
   Endocarditis                 39 (16.0)     12 (14.8)             27 (16.6)                
   Osteomyelitis                13 (5.3)      8 (9.9)               5 (3.1)                  
   Arthritis                    8 (3.3)       1 (1.2)               7 (4.3)                  
   Meningitis                   1 (0.4)       1 (1.2)               0                        
   Other                        20 (8.1)      5 (6.2)               15 (9.2)                 0.11
  Devices (%)                                                                                
   None                         133 (54.2)    57 (69.5)             76 (46.6)                
   Peripheral venous catheter   46 (18.8)     8 (9.8)               38 (23.3)                
   Central venous catheter      58 (23.7)     16 (19.5)             42 (25.8)                
   Other                        8 (3.3)       1 (1.2)               7 (4.3)                  0.004
  Comorbidity (%)                                                                            
   0                            71 (29.0)     34 (41.5)             37 (22.7)                
   1                            120 (49.0)    43 (52.4)             77 (47.2)                
   \>1                          54 (22.0)     5 (6.1)               49 (30.1)                0.0001
  Pitt score (%)                                                                             
   0--3                         216 (89.3)    75 (92.6)             141 (87.6)               
   \>3                          26 (10.7)     6 (7.4)               20 (12.4)                0.28
  Period (%)                                                                                 
   1995--1997 (pre-ART)         60 (24.5)     22 (26.8)             38 (23.3)                
   1997--1999 (early-ART)       51 (20.8)     28 (34.1)             23 (14.1)                
   2000 (late-ART)              134 (54.7)    32 (39)               102 (62.6)               0.0001

ART, antiretroviral therapy; IDU, injection drug use; MRSA, methicillin-resistant *Staphylococcus aureus.*

Among the individuals with HIV infection, the majority had community-acquired SAB (75.6%), followed by hospital-acquired (18.3%) and healthcare-associated SAB (4.9%). Among the individuals without HIV infection, fewer had community-acquired SAB (57.7%), and more had hospital-acquired (32.5%) and healthcare-associated SAB (9.8%). Active IDU was the primary focus of infection (43.9%) of individuals with HIV infection, followed by skin infection (20.7%), unknown (18.3%), peripheral or central line (12.2%), surgical (2.4%) and other (2.4%). The most common primary focus in individuals without HIV infection was skin infection (26.4%) followed by active IDU (25.2%), unknown (23.3%), peripheral or central line (11.7%), other (9.2%) and surgical (4.3%). Secondary manifestations were seen in 33.1% of all individuals and evenly distributed. The most common secondary manifestation was endocarditis (16.6% and 14.6%, respectively).

Comorbidity was frequent in HIV-uninfected individuals (77.3%), and 30.1% had more than one comorbidity. More than half of individuals with HIV infection had comorbidity (58.5%), but only 6.1% had one or more comorbidity.

As a measure of acute disease severity, Pitt score \>3 was more common among individuals without HIV infection (12.3%) than among HIV infected (7.4%).

Baseline vital and laboratory values are given in [table 2](#BMJOPEN2013004075TB2){ref-type="table"}. individuals with HIV infection had significantly lower total white cell count (WCC) (7.3 (0.2--41.2) vs 12.4 (0.4--36.0) × 10^9^/L), neutrophil count (5.1 (0.4--16.7) vs 9.7 (0.2--33.1) × 10^9^/L), lymphocyte count (0.7 (0.1--3.6) vs 0.9 (0.1--4.0) × 10^9^/L) and platelet count (175 (6--457) vs 215 (15--962) × 10^9^/L) compared with individuals without HIV infection. Values of plasma C reactive protein (CRP) and creatinine did not differ between groups.

###### 

Vital and laboratory characteristics of individuals with *Staphylococcus aureus* bacteraemia with and without HIV-1 infection

  --------------------------------------------------------------------------------------------------
                               All\                HIV-1 infected\     HIV-1 uninfected\   p Value
                               n=245               n=82                n=163               
  ---------------------------- ------------------- ------------------- ------------------- ---------
  Vitals                                                                                   

   Temperature (°C)            39.0 (28.7--41.0)   39.0 (34.7--40.7)   38.9 (28.7--41.0)   0.25

   Systolic BP (mm Hg)         112 (50--186)       110 (50--163)       117 (60--186)       0.07

  Laboratory values                                                                        

   B haemoglobin (10^9^/L)     6.5 (3.3--13.0)     6.5 (3.8--9.4)      6.6 (3.3--13.0)     0.34

   B WCC (10^9^/L)             10.75 (0.2--41.2)   7.3 (0.2--41.2)     12.4 (0.4--36.0)    0.0001

   B neutrophils (10^9^/L)     8.4 (0.2--33.1)     5.1 (0.4--16.7)     9.7 (0.2--33.1)     0.0001

   B lymphocytes (10^9^/L)     0.8 (0.1--4.0)      0.7 (0.1--3.6)      0.9 (0.1--4.0)      0.05

   B platelets (10^9^/L)       195 (6--962)        175 (6--457)        215 (15--962)       0.03

   P CRP (mg/L)                206 (5--3265)       233 (13--3252)      205 (5--3265)       0.33

   P creatinine (μmol/L)       78 (22--2006)       79 (42--987)        76,5 (22--2006)     0.82

   B CD4 T cells/µL            NA                  243 (47--421)       NA                  NA

   P HIV RNA (log copies/mL)   NA                  4.2 (2.3--4.9)      NA                  NA
  --------------------------------------------------------------------------------------------------

B, blood; BP, blood pressure; CRP, C reactive protein; NA, not available; P, plasma; WCC, white cell count.

Individuals with HIV infection tended to have a lower systolic blood pressure than individuals without HIV infection (110 (50--163) vs 117 (60--186) mm Hg, p=0.07).

Among the individuals with HIV infection, the CD4 T-lymphocyte count was 243 (47--421) cells/µL and HIV RNA 4.2 (2.3--4.9) log copies/mL.

Mortality {#s3a}
---------

There were 12 (14.6%) deaths within 30 days among individuals with HIV infection ([figure 1](#BMJOPEN2013004075F1){ref-type="fig"}). Among individuals without HIV infection, there were 16 (9.8%) deaths within 30 days. There were no statistically significant changes in mortality over time.

![Time to reinfection for individuals with and without HIVinfection. Log rank test: p=0.001.](bmjopen2013004075f01){#BMJOPEN2013004075F1}

Risk factors associated with 30-day mortality {#s3b}
---------------------------------------------

More than 90% complete data were available for HIV status, sex, age, nationality, origin, time period, IDU, entry, secondary manifestation, presence and type of foreign devices, comorbidity, Pitt score, antibiotic therapy, temperature, WCC and differential, platelet count, plasma CRP and plasma creatinine.

In univariate analysis, HIV status, age, comorbidity, IDU, platelet count, plasma creatinine, temperature, a foreign device and Pitt score were each associated with 30-day mortality. In multivariate analysis, including these variables, an increased risk of death at day 30 was associated with HIV infection (OR 11.90 (2.15 to 65.85)), age (OR 1.09 (1.02 to 1.16) per year increment), peripheral line vs no foreign device (OR 4.79 (1.01 to 22.69) and Pitt score (OR 35.07 (7.10 to 173.12) ([table 3](#BMJOPEN2013004075TB3){ref-type="table"}).

###### 

Multivariate analysis of risk factors associated with 30-day mortality from *Staphylococcus aureus* bacteraemia

                        30-Day                   
  --------------------- ------------------------ --------
  HIV infection                                  
   No                   1.0                      
   Yes                  11.90 (2.15 to 65.85)    0.005
  Age (years)                                    
   Per year increment   1.09 (1.02 to 1.16)      0.007
  Devices                                        
   None                 1.0                      
   Peripheral line      4.79 (1.01 to 22.69)     0.048
   Central line         0.52 (0.79 to 3.42)      0.12
   Other                --                       --
  Pitt score                                     
   0--3                 1.0                      
   \>3                  35.07 (7.10 to 173.12)   0.0001

In an analysis restricted to individuals with HIV infection, neither ART (OR 0.94 (0.23 to 3.88), AIDS (OR 2.99 (0.85 to 10.49), plasma HIV RNA viral load (OR 0.95 (0.57 to 1.59) per log increment) nor current (OR 0.86 (0.42 to 1.76) per log increment) or nadir (OR 0.99 (0.99 to 1.00)) CD4 T-lymphocyte count was associated with 30-day mortality.

Reinfection rates and risk factors {#s3c}
----------------------------------

Among individuals with HIV there were 24 reinfections during 309 person-years. These occurred within a median of 34 (4--100) months after the primary episode, yielding a reinfection rate of 7.8 (4.7--10.9)/100 person-years. During 864 person-years, there were 19 reinfections among individuals without HIV, a median of 13 (4--96) months after the primary episode, yielding a reinfection rate of 2.2 (1.2--3.2)/100 person-years ([figure 1](#BMJOPEN2013004075F1){ref-type="fig"}).

By logistic regression, we analysed factors associated with reinfection applying the same criteria as in the survival analysis, that is, \>90% complete data. In univariate analysis, age, sex, HIV status, entry, IDU, presence and type of foreign devices, comorbidity and secondary manifestation (endocarditis) were associated with reinfection. In multivariate analysis, HIV status and IDU remained associated with reinfection ([table 4](#BMJOPEN2013004075TB4){ref-type="table"}).

###### 

Risk factors associated with reinfection after *Staphylococcus aureus* bacteraemia

                       Crude OR (95% CI)      Adjusted OR (95% CI)   p Value
  -------------------- ---------------------- ---------------------- ---------
  HIV infection                                                      
   No (n=19)           1.0                    1.0                    
   Yes (n=24)          3.14 (1.60 to 6.16)    2.91 (1.29 to 6.58)    0.01
  Injection drug use                                                 
   Never (n=9)         1.0                    1.0                    
   Ever (n=34)         6.82 (3.10 to 15.02)   3.51 (1.06 to 11.63)   0.04

Clonal complexes {#s3d}
----------------

We identified 35 different CCs in 83 samples. Forty of 43 reinfections had paired isolates available for typing. In 27 (67.5%) of paired samples, the two CCs differed. Time to recurrence was not statistically different in cases of similar CCs compared to cases with different CCs (14 (4--73) vs 20 (5--95) months, p=0.14).

Discussion {#s4}
==========

In the current study, we found that individuals with HIV had a higher short-term mortality following SAB compared to individuals without HIV infection. Age, a peripheral line and disease severity but not HIV-related factors predicted mortality. HIV infection and IDU were associated with a higher rate of reinfection.

Mortality in our study was almost twice that reported by Furuno *et al*. Their study reported an in-hospital mortality of 7.6%.[@R20] The study had a similar proportion of IDUs as in our population but a higher proportion of right-sided endocarditis that may explain the better outcome. We report 30-day mortality, meanwhile Furuno *et al* report in-hospital mortality that may explain part of the difference seen. Studies in the pre-ART and early-ART periods have reported mortality rates of 19--22%.[@R16] [@R21] Almost two-thirds of patients in our study were treated in the pre-ART and early-ART period and this may explain the intermediate mortality rate.

Increasing age[@R3] [@R8] [@R9] [@R11] [@R16] [@R22] [@R23] and disease severity[@R1] [@R9] [@R16] are well-established risk factors of mortality in SAB in the general population, but these risk factors have not previously been evaluated in HIV infection. Here, we show that traditional risk factors also predict outcome in HIV-associated SAB. Interestingly, while a low CD4 count, high HIV RNA viral load and lack of ART are risk factors for acquisition of SAB,[@R6] none of these HIV-specific characteristics are associated with mortality. Interestingly, a peripheral intravenous line was a risk factor for mortality. The reason for this is not immediately clear, but we speculate that a peripheral catheter that was in place at the time of blood culture may be a marker of disease severity.

Haematological parameters were lower in individuals with HIV infection than in uninfected individuals but did not have an impact on outcome. Similar findings have previously been shown for other HIV-associated blood stream infections, including SAB and pneumococcal disease.[@R21] [@R24]

Individuals with HIV infection had a higher rate of reinfection putting them at risk of the infection and secondary manifestations once again, potentially affecting long-term mortality. Previous studies have reported HIV to be a significant risk factor for acquisition of SAB,[@R2] [@R6] and a recent population-based cohort study of comorbidity and risk of reinfection after SAB[@R7] found renal disease and HIV to be the strongest risk factors for reinfection. This supports our finding that HIV infection is associated with higher risk of reinfection. A history of IDU was also an independent risk factor for reinfection and is likely explained by active IDU with frequent breaching of the skin barrier. Active IDU was, accordingly, the most common source of entry for *S aureus* in the individuals with HIV infection.

Two-thirds of reinfections occurred with different CCs. However, the reinfections occurred more than 90 days (per definition in our study) after the initial episode with SAB, which we believe makes relapse unlikely. The cases with similar CCs in both isolates may be attributed to reinfection with colonising bacteria.

Limitations of this study are the small sample size and retrospective design. It is possible that the sample size was too small to show the impact of HIV-specific characteristics on mortality.

The age-matched controls were only able to be matched within a decade due to the relatively young age of individuals with HIV infection at SAB diagnosis. For this reason, we adjusted for age in all analysis. Individuals with HIV infection acquire SAB at a younger age[@R6] and the age of the patients included in this study is similar to that of patients in other studies examining HIV-associated SAB[@R4] [@R25] indicating that the results are applicable to the general HIV population.

Strengths of this study are the long study period, including pre-ART, early-ART and late-ART periods as well as the long follow-up time.

In conclusion, individuals with HIV infection have higher mortality and reinfection rates following SAB than individuals without HIV infection. Prevention of bloodstream infection with *S aureus* is therefore of high importance in patients infected with HIV.
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